Last updated: February 22, 2026
What is the Therapeutic Use of NDC 64380-0843?
NDC 64380-0843 corresponds to sodium zirconium cyclosilicate, marketed as Lokelma. It is approved for the treatment of hyperkalemia in adult patients. The drug functions by exchanging sodium ions for potassium in the gastrointestinal tract, lowering serum potassium levels.
Current Market Position and Penetration
Market Introduction and FDA Approval:
- Approved by the FDA in August 2018.
- Rapid adoption driven by the increasing prevalence of hyperkalemia, notably among patients with chronic kidney disease (CKD), heart failure, and those on renin-angiotensin-aldosterone system inhibitors.
- The drug gained market approval around a time when the prevalence of hyperkalemia in the U.S. exceeded 8 million patients according to CDC data.
Market Size and Adoption:
| Parameter |
Data/Estimate |
| U.S. hyperkalemia population |
8-10 million patients (per CDC and industry estimates) |
| Patients on dialysis or with CKD |
About 2.5 million (per CDC CKD data) |
| Market penetration (by 2022) |
Approximately 30% of the target population receiving Rx |
| Estimated annual sales (2022) |
$220 million (per EvaluatePharma and IQVIA estimates) |
Key Competitors:
- Patiromer (Veltassa)
- Sodium bicarbonate (less used)
- Hemodialysis (for severe cases)
Market Dynamics:
- Lokelma's side effect profile favors use over Patiromer, which has more GI-related adverse events.
- Use is expanding into outpatient markets and chronic management protocols.
- Insurance coverage is favorable, with strong payor adoption following CMS guidelines.
Price Trends and Regulatory Influences
Pricing History (Approximate):
| Year |
Wholesale Acquisition Cost (WAC) per 30 g container |
Notes |
| 2018 |
$400–$450 |
Launch pricing |
| 2020 |
$350–$400 |
Slight decrease due to market competition |
| 2022 |
$330–$370 |
Stabilized; slight downward trend observed |
Price Drivers:
- Patent exclusivity extended into 2030 due to FDA exclusivity periods and trial data protection.
- Discounting and rebate trends influence net prices.
- Generic development prospects are minimal, given the relatively recent approval and limited competition.
Future Market and Price Projections
Market Growth Assumptions
- Compound annual growth rate (CAGR) of 10% projected from 2023 to 2027.
- Continued increase in hyperkalemia prevalence driven by aging populations and CKD/heart failure rates.
- Expansion into outpatient and long-term management settings.
Price Projection (2023–2027)
| Year |
Average WAC per 30 g container |
Estimated Market Size |
Projected Revenue |
| 2023 |
$360 |
$250 million |
$250 million |
| 2024 |
$370 |
$275 million |
$280 million |
| 2025 |
$380 |
$300 million |
$300 million |
| 2026 |
$390 |
$330 million |
$330 million |
| 2027 |
$400 |
$360 million |
$360 million |
Market Drivers and Risks
Drivers:
- Increasing awareness of hyperkalemia management.
- Expanded clinical guidelines recommending the use of sodium zirconium cyclosilicate.
- Off-label use in patients with mild hyperkalemia experiencing recurrent episodes.
Risks:
- Development of generics post-patent expiration.
- Competitive pressure from improved therapies or alternative management strategies.
- Regulatory changes impacting pricing or reimbursement policies.
Key Takeaways
- NDC 64380-0843 (Lokelma) has captured a significant segment of the hyperkalemia treatment market since 2018.
- Current market size exceeds $200 million annually, with moderate growth driven by rising disease prevalence.
- Pricing has stabilized after initial premium positioning, with a slight downward adjustment over time.
- Market expansion into outpatient and long-term care settings will likely sustain revenues.
- Generics are unlikely before 2030; hence, current pricing power remains robust.
FAQs
1. What factors most influence the price of sodium zirconium cyclosilicate?
Pricing is affected by market penetration, competition from generics, insurance reimbursement policies, and manufacturer discount strategies.
2. How does the market for hyperkalemia treatments evolve with CKD prevalence?
As CKD rates increase, demand for effective hyperkalemia management grows, expanding the potential market for sodium zirconium cyclosilicate.
3. When will generics likely enter the market?
Patent exclusivity is expected to expire around 2030, after which generics could significantly impact pricing.
4. Are there regional variations in pricing?
Yes, prices vary between the U.S. and international markets, influenced by regulatory and reimbursement differences.
5. What are the primary drivers for future revenue growth?
Enhanced clinical use, expanded indications, and increased awareness of hyperkalemia management create upward pressure on sales.
References
[1] CDC. (2022). Chronic Kidney Disease Surveillance Report. Centers for Disease Control and Prevention.
[2] EvaluatePharma. (2022). Annual Report.
[3] FDA. (2018). Approval of Lokelma (sodium zirconium cyclosilicate).
[4] IQVIA. (2022). US Pharmaceuticals Market Data.
